BriaCell Receives Seventh Consecutive Positive DSMB Recommendation
News related to:BriaCell Therapeutics Corp · 1 min read
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has received a positive recommendation from its Data Safety Monitoring Board (DSMB) for its ongoing Phase 3 pivotal study of Bria-IMT™ plus an immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. This marks the seventh consecutive positive recommendation from the DSMB, reinforcing the favorable safety and tolerability profile of the treatment.
The DSMB, an independent group of experts, reviewed the clinical data from BriaCell’s Phase 3 Bria-ABC study (NCT06072612) and found no safety concerns. The board recommended that the study continue without modifications. DSMB meetings are held quarterly in accordance with the study protocol.
BriaCell’s Phase 3 study is being conducted under the FDA’s Fast Track designation, which underscores the significant unmet medical need in metastatic breast cancer. This designation is granted to drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address an unmet medical need.
Dr. William V. Williams, President and CEO of BriaCell, expressed encouragement regarding the DSMB’s recommendation.
The Bria-IMT™ treatment is part of BriaCell’s portfolio of novel immunotherapies aimed at transforming cancer care. The company’s ongoing study is a pivotal phase designed to evaluate the efficacy and safety of Bria-IMT™ in combination with an immune checkpoint inhibitor for patients with metastatic breast cancer.
The FDA’s Fast Track designation highlights the critical nature of the treatment and the urgent need for effective therapies in this patient population. BriaCell’s approach is designed to harness the body’s immune system to fight cancer, offering a potential transformative solution for patients suffering from metastatic breast cancer.
The positive DSMB recommendation is a significant step forward for BriaCell’s Phase 3 study and underscores the company’s commitment to advancing innovative cancer treatments. With the continued support of the DSMB, BriaCell is poised to make substantial progress in its mission to improve patient outcomes in the treatment of metastatic breast cancer.